Discuss Abbott Laboratories
Abbott Laboratories
WKN: 850103 / Symbol: ABT / Name: Abbott / Aktie / Pharmazeutika / Large Cap /
109,54 €
0,20 %
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Barclays PLC from $143.00 to $149.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Evercore ISI to $136.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $135.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at UBS Group AG from $146.00 to $148.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Stifel Nicolaus from $130.00 to $135.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Wells Fargo & Company from $133.00 to $136.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $158.00 price target on the stock, up previously from $149.00.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) was upgraded by analysts at Argus to a "strong-buy" rating.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $138.00 to $154.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Citigroup Inc. from $135.00 to $160.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Bank of America Co. from $133.00 to $150.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Stifel Nicolaus from $135.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Barclays PLC from $158.00 to $159.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Wells Fargo & Company from $136.00 to $147.00. They now have an "overweight" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Royal Bank of Canada from $140.00 to $145.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $145.00 price target on the stock, up previously from $133.00.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Raymond James from $132.00 to $142.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Evercore ISI from $140.00 to $145.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target raised by analysts at Royal Bank Of Canada from $145.00 to $147.00. They now have an "outperform" rating on the stock.
Ratings data for ABT provided by MarketBeat
Abbott Laboratories (NYSE: ABT) had its price target lowered by analysts at BTIG Research from $148.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for ABT provided by MarketBeat
Neueste Beiträge
BMO_Capital_Markets in Amazon.com Inc. diskutieren